Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1575

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 5
Chunk 1575
---
Market Information

Our common stock has been listed
under the symbol “XAIR” on the Nasdaq Capital Market since May 7, 2019. From August 28, 2018 until May 6, 2019, our common
stock was quoted on the OTC Pink.

On June 18, 2025, the closing price for our common
stock as reported on The Nasdaq Capital Market was $0.2023 per share.

Stockholders

As of June 18, 2025, there were
approximately 97 holders of record for shares of our common stock. This does not reflect beneficial stockholders who held their common
stock in “street” or nominee name through brokerage firms.

Securities Authorized
for Issuance Under Equity Compensation Plans

Information regarding securities
authorized for issuance under our equity compensation plans is contained in Part III, Item 12 of this Annual Report.

Dividend Policy

We have never declared or paid
any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations
and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable
future.

Unregistered Sales of Equity Securities

(a) Sales of Unregistered Securities

During the year ended March 31, 2025, the Company
issued only unregistered equity securities previously reported in the Current Reports on Form 8-K and in the Quarterly Reports on Form
10-Q filed by the Company with the SEC.

(b) Use of Proceeds

None.

(c) Issuer Purchases of Equity Securities

None.

ITEM 6. [RESERVED]

75

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and
analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements
and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report contain
forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions
and projections. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could
cause or contribute to such differences include, but are not limited to, those discussed in Item 1A “Risk Factors.”

Introduction

We are a commercial-stage medical
device and biopharmaceutical company developing a platform of nit